Suono Bio news
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including gene therapies, throughout the gastrointestinal tract.
Suono Bio is advancing
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract.
This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has raised an $8.5 million Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors. Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline. Suono Bio’s platform technology enables the rapid, targeted delivery of drugs
Suono Bio, Inc. announced today a strategic investment by FUJIFILM Corporation to advance Suono Bio’s second-generation platform technology for the ultra-rapid, formulation-independent administration of therapeutics including biologics and gene therapies.
Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious disea